Molecular and cytogenetic workflow for imatinib-treated patients according to the recommendations of an expert panel. Mutation analysis is recommended in case of failure to achieve a complete hematologic response after 3 months of imatinib therapy, a major cytogenetic response (≤35% Ph chromosome) after 6 months, a complete cytogenetic response (CCR) after 12 months and a major molecular response (MMR) after 18 months. Loss of these responses, progression to accelerated phase or blast crisis or a significant rise in BCR-ABL according to the measurement reliability of the RQ-PCR assay should also initiate mutation analysis.¹